Status:
COMPLETED
Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
The purpose of this research study is to evaluate a newer imaging technique, called 18F-Sodium Fluoride (NaF) positron emission tomography (PET). NaF is a tracer (dye) that is very sensitive for chang...
Detailed Description
The study will look at how repeatable the NaF PET scans are before treatment. Scans will also be performed after standard chemotherapy or hormone-directed treatment. This will allow evaluation of how ...
Eligibility Criteria
Inclusion
- Histologically confirmed adenocarcinoma of the prostate
- Identifiable prostate cancer-related bone metastases on bone scan in the spine, pelvis or other bone
- Patients must be starting a microtubule directed chemotherapy regimen for metastatic castrate-resistant prostate cancer OR
- Patients must be starting a AR-directed regimen (e.g. Abiraterone, MDV-3100, TAK-700, etc) for treatment of metastatic castrate-resistant prostate
Exclusion
- Concurrent treatment with any other agent that is being used with the expressed purpose of treating of prostate cancer outside of the planned treatment regimen
- Patients who have received radiotherapy less than 4 weeks prior to registration.
- Patients who have received prior Strontium-89, Samarium-153, or other radioisotope.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to sodium fluoride F-18 (NaF).
Key Trial Info
Start Date :
November 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2018
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT01516866
Start Date
November 1 2011
End Date
January 1 2018
Last Update
November 18 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute
Bethesda, Maryland, United States, 20892
2
Memorial Sloan Kettering
New York, New York, United States, 10065
3
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States, 53792